UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

Value in health, 2012-12, Vol.15 (8), p.1162-1171

2012

Volltextzugriff (PDF)

Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line Sunitinib

Value in health, 2011-09, Vol.14 (6), p.846-851

2011

Volltextzugriff (PDF)

HOUT-18. COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE

Neuro-oncology (Charlottesville, Va.), 2018-11, Vol.20 (suppl_6), p.vi116-vi117

2018

Volltextzugriff (PDF)

Abstract LB-257: Tumor treating fields treatment for patients with newly diagnosed glioblastoma: A cost-effectiveness analysis

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.LB-257-LB-257

2018

Volltextzugriff (PDF)

Sustainability of Universal Health Coverage: Five Continents, Four Perspectives

Value in health, 2013, Vol.16

GARRISON, Lou

2013

Volltextzugriff (PDF)

HOUT-16. THE COST EFFECTIVENESS OF TUMOR TREATING FIELDS TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA BASED ON THE EF-14 TRIAL

Neuro-oncology (Charlottesville, Va.), 2018-11, Vol.20 (suppl_6), p.vi116-vi116

2018

Volltextzugriff (PDF)

HOUT-18. COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE

Neuro-oncology (Charlottesville, Va.), 2018-11, Vol.20 (suppl_6), p.vi116-vi117

2018

Volltextzugriff (PDF)

495 - Estimating the Current and Future Costs and Health Outcomes of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HCT)

Transplantation and cellular therapy, 2023-02, Vol.29 (2), p.S371-S371

2023

Volltextzugriff (PDF)

Estimating the Current and Future Costs and Health Outcomes of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HCT)

Transplantation and cellular therapy, 2023-02, Vol.29 (2), p.S371

2023

Volltextzugriff (PDF)

Extending the reach of public health genomics: What should be the agenda for public health in an era of genome-based and “personalized” medicine?

Genetics in medicine, 2010-12, Vol.12 (12), p.785-791

2010

Volltextzugriff (PDF)

What principles should govern the use of managed entry agreements?

International journal of technology assessment in health care, 2011-01, Vol.27 (1), p.77-83

2011

Volltextzugriff (PDF)

The Drug Budget Silo Mentality in Europe: An Overview

Value in health, 2003-07, Vol.6 (s1), p.S1-S9

2003

Volltextzugriff (PDF)

A CORRELATIONAL STUDY OF FACTORS UTILIZED IN COUNSELOR CANDIDATE SELECTION AT WESTERN MICHIGAN UNIVERSITY

GARRISON, MARY LOU

1967

Volltextzugriff (PDF)

Recurrent evolution and selection shape structural diversity at the amylase locus

Nature (London), 2024-10, Vol.634 (8034), p.617-625

2024

Volltextzugriff (PDF)

Frequency of Indeterminate Western Blot Tests in Healthy Adults at Low Risk for Human Immunodeficiency Virus Infection

The Journal of infectious diseases, 1990-12, Vol.162 (6), p.1379-1382

1990

Volltextzugriff (PDF)

Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay

AIDS research and human retroviruses, 1990-11, Vol.6 (11), p.1251-1256

1990

Volltextzugriff (PDF)

Retention of Homeless Clients in Substance Abuse Treatment: Findings From the National Institute on Alcohol Abuse and Alcoholism Cooperative Agreement Program

Journal of substance abuse treatment, 1999-07, Vol.17 (1), p.45-66

1999

Volltextzugriff (PDF)

Retention of Homeless Clients in Substance Abuse Treatment

Journal of substance abuse treatment, 1999-07, Vol.17 (1-2), p.45-66

1999

Volltextzugriff (PDF)

1 – 18 von 18

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieCancer Biotherapy & Radiopharmaceuticals

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(15)
Mit Volltextzugriff
(15)

Publikationsform

Erscheinungsjahr

n.n

Thema

Science & Technology
(9)
Life Sciences & Biomedicine
(8)
Humans
(6)
Biological And Medical Sciences
(4)
Health Care Sciences & Services
(4)
Social Sciences
(4)
Business & Economics
(3)
Economics
(3)
Health Policy & Services
(3)
Abstracts
(2)
Budgets
(2)
Economics, Pharmaceutical
(2)
Fundamental And Applied Biological Sciences. Psychology
(2)
Health
(2)
Health Technology Assessment
(2)
Immunology
(2)
Infectious Diseases
(2)
Internal Medicine
(2)
Medical Sciences
(2)
Microbiology
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line Sunitinib

HOUT-18. COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE

Abstract LB-257: Tumor treating fields treatment for patients with newly diagnosed glioblastoma: A cost-effectiveness analysis

Sustainability of Universal Health Coverage: Five Continents, Four Perspectives

HOUT-16. THE COST EFFECTIVENESS OF TUMOR TREATING FIELDS TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA BASED ON THE EF-14 TRIAL

HOUT-18. COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE

495 - Estimating the Current and Future Costs and Health Outcomes of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HCT)

Estimating the Current and Future Costs and Health Outcomes of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HCT)

Extending the reach of public health genomics: What should be the agenda for public health in an era of genome-based and “personalized” medicine?

What principles should govern the use of managed entry agreements?

The Drug Budget Silo Mentality in Europe: An Overview

A CORRELATIONAL STUDY OF FACTORS UTILIZED IN COUNSELOR CANDIDATE SELECTION AT WESTERN MICHIGAN UNIVERSITY

Recurrent evolution and selection shape structural diversity at the amylase locus

Frequency of Indeterminate Western Blot Tests in Healthy Adults at Low Risk for Human Immunodeficiency Virus Infection

Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay

Retention of Homeless Clients in Substance Abuse Treatment: Findings From the National Institute on Alcohol Abuse and Alcoholism Cooperative Agreement Program

Retention of Homeless Clients in Substance Abuse Treatment

Aktive Filter

Suchergebnisse filtern